title: [Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis].
abstract: Breast cancer disease and as well as CMF-chemotherapy are associated with an increased risk for thromboembolic complications. There is evidence that effects on the hemostatic system may play an important role. To minimize the impact of tumor associated hypercoagulability, we choose to study CMF-associated effects on the hemostatic system within an adjuvant setting. Blood coagulation and fibrinolysis were examined before and 24 hours after intravenous application of CMF-therapy at 17 patients with breast cancer. 16 parameters of coagulation and fibrinolysis were studied. In a longitudinal analysis covering the complete 6 month treatment period we found a decrease of thromboplastin time (TPZ) factor VII (FVII) and protein C antigen (PC Ag) and activity (PC Act). Clinically relevant pathological results and cumulative effects were observed only for PC Ag and Act, while the mean values of TPZ and FVII returned to pre-treatment levels after each course of treatment. These data suggest a potential impact of CMF-chemotherapy on synthesis and activation of vitamin-K-dependent coagulation factors thus providing a possible explanation for the increased risk for thrombosis during CMF-chemotherapy.
authors.affiliation: Abt. für Gynäkologie, Universitätsklinikum Essen.
authors.forename: C
authors.initials: C
authors.lastname: Oberhoff
authors.forename: U H
authors.initials: UH
authors.lastname: Winkler
authors.forename: A M
authors.initials: AM
authors.lastname: Tauchert
authors.forename: A E
authors.initials: AE
authors.lastname: Schindler
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000302:isolation & purification; D001780:Blood Coagulation Tests; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D008137:Longitudinal Studies; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013927:Thrombosis / Q000139:chemically induced
chemical_list: D001779:Blood Coagulation Factors; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate